Brain Metabolic Activity Measured by [(18)F]FDG PET/CT Predicts Survival in Patients with Advanced Non-Small Cell Lung Cancer

Lung, Respiratory and Thoracic Cancer

Survival and prognostic factors of HER2-mutant advanced non-small cell lung cancer with brain metastases

Lung Cancer

Zhang Q, Yang Y, Xie M, Zhou Z, Wu H, Zhai W, Chen Y, Chen K, Zhou S, Li H, Fan Y

doi: 10.1016/j.lungcan.2025.108616

Lung, Respiratory and Thoracic Cancer

Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis

Lancet Oncol

Di Federico A, Stumpo S, Mantuano F, De Giglio A, Lo Bianco F, Pecci F, Alessi JV, Wang X, Sperandi F, Melotti B, Gelsomino F, Skoulidis F, Garassino MC, Peters S, Awad MM, Ardizzoni A, Ricciuti B

doi: 10.1016/S1470-2045(25)00429-2

Lung, Respiratory and Thoracic Cancer

Clinical risk factors for developing brain metastases during first-line (chemo-)immunotherapy in patients with non-small cell lung cancer without known baseline brain metastases

Lung Cancer

Huijs JWJ, Sadowska AM, Degens JHRJ, Steendam CMJ, Bensch F, Hijmering-Kappelle LBM, de Schrevel TMT, van Geffen WH, Youssef-El Soud M, Steens MMH, Pitz C, De Ruysscher DKM, Hendriks LEL

doi: 10.1016/j.lungcan.2025.108745

Lung, Respiratory and Thoracic Cancer

Real-World Treatment Patterns and Survival in Patients with ROS1-Positive Advanced Non-Small Cell Lung Cancer in Canada and Europe

Curr Oncol

Cheung WY, Lee A, Bote de Cabo H, Burdenski K, Christopoulos P, Pinto-Correia B, Deshayes S, Girard N, Hindocha P, Madden Á, Mella M, Moreira J, Rizzi S, Abreu DR, Soares M, Thomas J, Han M, Calvet CY, Emanuel G, Glassberg MB, Jacobs H, Rault C, Yuan Y, Chouaid C

doi: 10.3390/curroncol33030152

Lung, Respiratory and Thoracic Cancer

Immune-inflammatory predictors of early and brain recurrence in young patients with resected non-small cell lung cancer

Lung Cancer

Brascia D, Mangiameli G, Congedo MT, Mastromarino MG, Catelli C, Schiavon M, Giudici V, Senatore A, Bonis A, Lucchi M, Luzzi L, Magaritora S, Rea F, Marulli G

doi: 10.1016/j.lungcan.2026.108946

Lung, Respiratory and Thoracic Cancer

Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trial

Lung Cancer

Dingemans AC, Syrigos K, Livi L, Paulus A, Kim SW, Chen Y, Felip E, Griesinger F, Ohashi K, Zalcman G, Hughes BGM, Sørensen JB, Blais N, Ferreira CGM, Lindsay CR, Dziadziuszko R, Ward PJ, Obiozor CC, Wang Y, Peters S

doi: 10.1016/j.lungcan.2025.108683

Lung, Respiratory and Thoracic Cancer

First-line immunotherapy ± chemotherapy with or without upfront stereotactic radiotherapy (SRT) in patients with Non-Small cell lung cancer (NSCLC) with asymptomatic brain metastases

Lung Cancer

Frehner L, Schär S, Hayoz S, Petermichl V, Speicher P, I Rothschild S, Mauti LA, König D, Finazzi T, Froesch P, Marini S, Allemann A, Mark M, Janthur WD, Stamatiou A, Metaxas Y, Ermiş E, Wagner F, Früh M, Schmid S

doi: 10.1016/j.lungcan.2025.108813

Lung, Respiratory and Thoracic Cancer

Immune checkpoint inhibitors for advanced non-small cell lung cancer with preexisting COPD and CT-defined emphysema: A systematic review and meta-analysis

Lung Cancer

Zhang Y, Zhao J, Ma Z, Yi J, Yuan Y, Lang L, Zhang C, Zhu M, Zhang Y

doi: 10.1016/j.lungcan.2025.108700

Lung, Respiratory and Thoracic Cancer

Advanced-stage ALK-positive non-small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database

Lung Cancer

Reale ML, Scattolin D, Vitale A, Passiglia F, Grisanti S, Macerelli M, Galetta D, Sini C, Minuti G, Citarella F, Roca E, Agustoni F, Dodi A, Cortinovis D, Belluomini L, Ricciardi S, Veccia A, Pizzutilo EG, Scotti V, Alì G, Mazzoni F, Russo A, Pignataro D, Bulotta A, Piovano P, Sergi C, Bettini A, Genova C, Pavan A, Soto Parra HJ, Ortega C, Pozzessere D, Vavalà T, Chiari R, Zannori C, D'Aveni A, Meoni G, Giannarelli D, Malapelle U, Novello S, Bria E, Pasello G

doi: 10.1016/j.lungcan.2025.108762

Related content

Survival and prognostic factors of HER2-mutant advanced non-small cell lung cancer with brain metastases

Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis

Clinical risk factors for developing brain metastases during first-line (chemo-)immunotherapy in patients with non-small cell lung cancer without known baseline brain metastases

Real-World Treatment Patterns and Survival in Patients with ROS1-Positive Advanced Non-Small Cell Lung Cancer in Canada and Europe

Immune-inflammatory predictors of early and brain recurrence in young patients with resected non-small cell lung cancer

Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trial

First-line immunotherapy ± chemotherapy with or without upfront stereotactic radiotherapy (SRT) in patients with Non-Small cell lung cancer (NSCLC) with asymptomatic brain metastases

Immune checkpoint inhibitors for advanced non-small cell lung cancer with preexisting COPD and CT-defined emphysema: A systematic review and meta-analysis

Advanced-stage ALK-positive non-small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database